Background
Schistosomiasis is a debilitating neglected tropical disease that affects approximately 190 million people around the world. Praziquantel (PZQ) is the only drug available for use against all
Schistosoma
species. Although PZQ has a high efficacy, recognized concerns have prompted the development of new, alternative drugs for repeated use in endemic areas where PZQ efficacy against strains of
Schistosoma
is reduced. A hybrid drug containing different pharmacophores within a single molecule is a promising strategy. Our earlier
in vivo
studies showed the significant antiparasitic activity of a praziquantel derivative, DW-3-15, against
Schistosoma japonicum
. In the present study, DW-3-15 was synthesized in large amounts by a pharmaceutical company and its schistosomicidal efficacy and stability were further confirmed. Parameters such as parasite viability, pairing and oviposition were evaluated
in vitro
. An
in vivo
study was conducted to assess the effect of commercial DW-3-15 on worm burden, egg production and diameter of granulomas. Additionally, to gain insight into the mechanism of action for DW-3-15, morphological changes in the tegument of
S. japonicum
were also examined.
Results
The
in vitro
study showed the antiparasitic activity of DW-3-15 against
S. japonicum
, with significant reductions in viability of adult and juvenile worms, worm pairings and egg output. Compared to PZQ, DW-3-15 induced similar ultrastructural changes and evident destruction of the tegument surface in male worms.
In vivo
, the oral administration of DW-3-15 at a dose of 400 mg/kg per day for five consecutive days in mice significantly reduced the total worm burden and number of eggs in the liver. Histological analysis of the livers showed a marked reduction in the average diameter of the egg granuloma.
Conclusions
Our findings suggest that DW-3-15, a PZQ derivative with the prospect of commercial production, can be developed as a potential promising schistosomicide.
Electronic supplementary material
The online version of this article (10.1186/s13071-019-3442-7) contains supplementary material, which is available to authorized users.